I
Inivata
Clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis
About Inivata
Inivata is a pioneering company in the field of liquid biopsy, a technology that extracts key genomic information from a simple blood test to revolutionize cancer care. The company primarily serves patients with advanced Non-Small Cell Lung Cancer (NSCLC) and high-grade ovarian carcinomas (HGOC). Operating in the healthcare and biotechnology markets, Inivata collaborates with medical institutions and pharmaceutical companies to provide cutting-edge diagnostic solutions. Its business model revolves around the development and commercialization of liquid biopsy assays, which are used for detecting residual disease and recurrence in cancer patients. Revenue is generated through the sale of these diagnostic tests and through strategic partnerships and collaborations, such as the one with Maverick Therapeutics. Inivata's innovative approach and commitment to improving patient outcomes make it a leader in its field.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2014
- Headquarters
- Morrisville, United States
- Employees
- 36
- Open positions
- None listed
- Dealroom signal
- 62.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Analytics, Biotechnology, Oncology, DNA, Genetics and genomics, Non-Invasive medical devices and treatments, Spinout, Genome Engineering, Biotech and Pharma, UKSU
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2021 | $390M | $500M | NeoGenomics Laboratories | — |
| SERIES COther financing | Feb 2021 | $35M | $140M | Farallon Capital Management · Janus Henderson Investors · IP Group · Soleus Capital | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Inivata is 760 monthly website visits, down 45.7% over the last three months. Inivata's team declined 71.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Johnson & Johnson
Imperial Innovations
Cambridge Innovation Capital
Woodford Investment Management
IP Group
Johnson & Johnson Innovation
RT Ventures
Series B and later4 investors entered at this stage
NeoGenomics Laboratories- SCSoleus Capital
Farallon Capital Management
Janus Henderson Investors
Other known investors1 additional known investor
University of Cambridge
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Inivata on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Inivata’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.